Pfizer has settled an ongoing battle with Teva Pharmaceuticals and several other parties to prevent the sale of Teva’s copycat version of the world’s best-selling drug, Lipitor (atorvastatin).

Under the terms of the agreement Teva, Phoenix Healthcare Distribution, Barclay Pharmaceuticals, AAH Pharmaceuticals, L Rowland & Co and Day Lewis will not the generic before May 2012, when the patent expires.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Pfizer commenced legal proceedings against Teva and three major wholesalers in July.

Upon the decision of a full trial, Pfizer said in a statement that Teva acknowledges that the Lipitor patent is valid and infringed by Teva’s product.

In November, Pfizer will launch a chewable low-dose version of Lipitor in the EU.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact